A Physiological Function of Inflammation-Associated SerpinB2 Is Regulation of Adaptive Immunity
暂无分享,去创建一个
Andreas Suhrbier | A. Suhrbier | W. Schroder | Ranjeny Thomas | J. Gardner | L. Major | T. Le | K. Markey | Ranjeny Thomas | R. Fish | Joy Gardner | Lee Major | Wayne A. Schroder | Richard J. Fish | Thuy T. T. Le | Shayna Street | Eleanore Lambley | Kate Markey | Kelli P. MacDonald | Eleanore H. Lambley | S. Street | K. Macdonald | Shayna E. A. Street
[1] B. Illades-Aguiar,et al. A Functional Ser413/Ser413 PAI-2 Polymorphism Is Associated With Susceptibility and Damage Index Score in Systemic Lupus Erythematosus , 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[2] M. Degli-Esposti,et al. Graft-versus-host disease prevents the maturation of plasmacytoid dendritic cells , 2009, The Journal of Immunology.
[3] F. Dammacco,et al. Overexpression of interleukin‐12 and T helper 1 predominance in lupus nephritis , 2008, Clinical and experimental immunology.
[4] S. Gaffen,et al. A New Inflammatory Cytokine on the Block: Re-thinking Periodontal Disease and the Th1/Th2 Paradigm in the Context of Th17 Cells and IL-17 , 2008, Journal of dental research.
[5] G. Heda,et al. Role of tissue-type plasminogen activator in salicylic acid-induced sloughing of human corn tissue. , 2008, Journal of the American Podiatric Medical Association.
[6] A. Suhrbier,et al. SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival. , 2008, Cancer research.
[7] M. Eisenacher,et al. Gene expression in periodontal tissues following treatment , 2008, BMC Medical Genomics.
[8] N. Buduneli,et al. Gingival crevicular fluid PGE2, IL-1beta, t-PA, PAI-2 levels in type 2 diabetes and relationship with periodontal disease. , 2008, Clinical biochemistry.
[9] David R. Croucher,et al. Revisiting the biological roles of PAI2 (SERPINB2) in cancer , 2008, Nature Reviews Cancer.
[10] A. Suhrbier,et al. Kunjin replicon-based simian immunodeficiency virus gag vaccines , 2008, Vaccine.
[11] Francesco Boin,et al. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. , 2008, Arthritis and rheumatism.
[12] J. Priatel,et al. Critical role for IFN‐γ in natural killer cell‐mediated protection from diabetes , 2008 .
[13] I. Scroyen,et al. Deficiency of plasminogen activator inhibitor‐2 impairs nutritionally induced murine adipose tissue development , 2007, Journal of thrombosis and haemostasis : JTH.
[14] R. Wilensky,et al. The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation , 2007, Current opinion in cardiology.
[15] Yee Hwa Yang,et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids , 2007, Proceedings of the National Academy of Sciences.
[16] M. Neuenhahn,et al. NF-κB Is a Negative Regulator of IL-1β Secretion as Revealed by Genetic and Pharmacological Inhibition of IKKβ , 2007, Cell.
[17] Nicole Cloonan,et al. Human Sin1 contains Ras-binding and pleckstrin homology domains and suppresses Ras signalling. , 2007, Cellular signalling.
[18] B. León,et al. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. , 2007, Immunity.
[19] Y. Sasaki,et al. The role of the immune system in preeclampsia. , 2007, Molecular aspects of medicine.
[20] A. Franx,et al. Inflammatory Changes in Preeclampsia: Current Understanding of the Maternal Innate and Adaptive Immune Response , 2007, Obstetrical & gynecological survey.
[21] C. Best-Aguilera,et al. Genotype Ser413/Ser of PAI‐2 polymorphism Ser413/Cys is associated with anti‐phospholipid syndrome and systemic lupus erythematosus in a familial case: comparison with healthy controls , 2007, Scandinavian journal of rheumatology.
[22] T. Poll,et al. Plasminogen Activator Inhibitor Type-1-Deficient Mice Have an Enhanced IFN-γ Response to Lipopolysaccharide and Staphylococcal Enterotoxin B1 , 2006, The Journal of Immunology.
[23] D. Harrich,et al. SerpinB2 Is an Inducible Host Factor Involved in Enhancing HIV-1 Transcription and Replication* , 2006, Journal of Biological Chemistry.
[24] L. Hawthorn,et al. Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease. , 2006, Blood.
[25] S. Abdulkadir,et al. Effects of Histone Deacetylase Inhibitor (HDACi); Trichostatin-A (TSA) on the expression of housekeeping genes. , 2006, Molecular and cellular probes.
[26] A. Giordano,et al. Cytoplasmic and nuclear interaction between Rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells , 2006, Cell Death and Differentiation.
[27] E. Kruithof,et al. Evidence for serpinB2-independent protection from TNF-alpha-induced apoptosis. , 2005, Experimental cell research.
[28] A. Hoffmann,et al. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators. , 2005, Immunity.
[29] S. Madoiwa,et al. Protection of Plasminogen Activator Inhibitor-1-Deficient Mice from Nasal Allergy1 , 2005, The Journal of Immunology.
[30] S. Lobov,et al. Structural bases of the redox-dependent conformational switch in the serpin PAI-2. , 2004, Journal of molecular biology.
[31] S. Smola,et al. High plasminogen activator inhibitor type 2 expression is a hallmark of scleroderma fibroblasts in vitro , 2004, Experimental dermatology.
[32] J. Whisstock,et al. Human clade B serpins (ov-serpins) belong to a cohort of evolutionarily dispersed intracellular proteinase inhibitor clades that protect cells from promiscuous proteolysis , 2004, Cellular and Molecular Life Sciences CMLS.
[33] J. Foekens,et al. Predictive Impact of Urokinase-Type Plasminogen Activator , 2004, Cancer Research.
[34] M. Gyetko,et al. Urokinase-Deficient Mice Fail To Generate a Type 2 Immune Response following Schistosomal Antigen Challenge , 2004, Infection and Immunity.
[35] T. Ulutin,et al. PCR-RFLP Detection of PAI-2 Variants in Myocardial Infarction , 2003, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[36] D. Harrich,et al. Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif , 2003, Molecular and Cellular Biology.
[37] P. Robbins,et al. TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis , 2003, Annals of the rheumatic diseases.
[38] Xia Wang,et al. Identification of interaction between PAI-2 and IRF-3. , 2003, Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica.
[39] C. Sweep,et al. Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. , 2002, American journal of obstetrics and gynecology.
[40] R. Medcalf,et al. Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. , 2002, Blood.
[41] B. Kinnby. The Plasminogen Activating System in Periodontal Health and Disease , 2002, Biological chemistry.
[42] N. Van Rooijen,et al. CLODRONATE LIPOSOMES: PERSPECTIVES IN RESEARCH AND THERAPEUTICS , 2002, Journal of liposome research.
[43] Mitsuaki Suzuki,et al. Expansion of the Fraction of Th1 Cells in Women with Preeclampsia: Inverse Correlation between the Percentage of Th1 Cells and the Plasma Level of PAI‐2 , 2001, American journal of reproductive immunology.
[44] T. Ninomiya,et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. , 2001, Arthritis and rheumatism.
[45] R. Appelberg,et al. Interleukin‐6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine , 2001, Immunology.
[46] J. Vassalli,et al. Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. , 2001, Cancer research.
[47] D. Hume,et al. Regulation of the plasminogen activator inhibitor‐2 (PAI‐2) gene in murine macrophages. Demonstration of a novel pattern of responsiveness to bacterial endotoxin , 1999, Journal of leukocyte biology.
[48] M. Gyetko,et al. Urokinase is required for T lymphocyte proliferation and activation in vitro. , 1999, The Journal of laboratory and clinical medicine.
[49] R. Westrick,et al. The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[50] N. Booth,et al. Secretion of plasminogen activator inhibitor 2 by human peripheral blood monocytes occurs via an endoplasmic reticulum-golgi-independent pathway. , 1998, Experimental cell research.
[51] P. Jensen,et al. Regulation of the level and glycosylation state of plasminogen activator inhibitor type 2 during human keratinocyte differentiation. , 1998, Differentiation; research in biological diversity.
[52] J. Dickinson,et al. The Serine Proteinase Inhibitor (Serpin) Plasminogen Activation Inhibitor Type 2 Protects against Viral Cytopathic Effects by Constitutive Interferon α/β Priming , 1998, The Journal of experimental medicine.
[53] C. Foy,et al. PCR-RFLP Detection od PAI-2 Gene Variants: Prevelence in Ethnic Groups and Disease Relationship in patients Undergoing corony Angiography , 1997, Thrombosis and Haemostasis.
[54] J. Gilabert,et al. Decreased Expression of PAI-2 mRNA and Protein in Pregnancies Complicated with Intrauterine Fetal Growth Retardation , 1996, Thrombosis and Haemostasis.
[55] T. Jensen,et al. The Exon 3 Encoded Sequence of the Intracellular Serine Proteinase Inhibitor Plasminogen Activator Inhibitor 2 Is a Protein Binding Domain* , 1996, The Journal of Biological Chemistry.
[56] M. Baker,et al. Biological and clinical aspects of plasminogen activator inhibitor type 2. , 1995, Blood.
[57] J. Dickinson,et al. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. , 1995, The Journal of biological chemistry.
[58] N. Booth,et al. Thrombin modulates synthesis of plasminogen activator inhibitor type 2 by human peripheral blood monocytes. , 1995, Blood.
[59] H. Gan,et al. Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with Mycobacterium avium, serovar 4. , 1995, Journal of immunology.
[60] J. Alexander,et al. The demonstration of an essential role for macrophages in the in vivo generation of IgG2a antibodies , 1994, Clinical and experimental immunology.
[61] F. D’Acquisto,et al. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation , 2009, Nature Reviews Immunology.
[62] Alberto Mantovani,et al. Macrophage activation and polarization. , 2008, Frontiers in bioscience : a journal and virtual library.
[63] M. Akahoshi,et al. Th1/Th2 balance of SLE patients with lupus nephritis. , 2006, Rinsho byori. The Japanese journal of clinical pathology.
[64] Xia Wang,et al. Interaction of plasminogen activator inhibitor-2 and proteasome subunit, beta type 1. , 2004, Acta biochimica et biophysica Sinica.
[65] Jingfan,et al. Interaction of Plasminogen Activator Inhibitor-2 and Proteasome Subunit, Beta Type 1 , 2004 .
[66] Y. Matsuda,et al. Suppression of keratinocyte proliferation by plasminogen activator inhibitor-2. , 1999, The Journal of investigative dermatology.